Key facts
- BreezeBio’s last known valuation is $234.0M (Feb 2026).
- It has raised $117.0M; the latest was Later Stage VC ($60.0M) in Feb 2026.
- Notable investors include US National Science Foundation, Sequoia Capital, KB Investment, Korea Investment Partners, Qiming Venture Partners — 39 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 39 names
- ·Watchlist + deal alerts for BreezeBio
- ·The full record, as it builds
Funding rounds
No funding rounds for BreezeBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BreezeBio
Developer of curative therapies designed for current gene therapy delivery challenges by systematically screening its proprietary nanoparticle library. The company's tool makes therapeutic gene editing possible and is easier to use, faster, and more accurate than previous gene-editing techniques, and also has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases, and also provides safer and more efficient delivery to target tissues.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2016
- Employees
- 63
- Website
- breezebio.com/
- Ownership
- Privately Held (backing)
BreezeBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BreezeBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BreezeBio in its N-PORT filings yet. We sweep new filings monthly.